Hyman DM - Search Results

1

Measuring Toxicity in Phase I Clinical Trials--Letter.

Hyman DM, Eaton A, Ivy SP, Spriggs DR, Iasonos A. Hyman DM, et al. Clin Cancer Res. 2016 Apr 1;22(7):1828. doi: 10.1158/1078-0432.CCR-15-3043. Clin Cancer Res. 2016. PMID: 27037257 No abstract available.

2

The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.

Iasonos A, Gounder M, Spriggs DR, Gerecitano JF, Hyman DM, Zohar S, O'Quigley J. Iasonos A, et al. Among authors: hyman dm. Clin Cancer Res. 2012 Oct 1;18(19):5179-87. doi: 10.1158/1078-0432.CCR-12-0726. Epub 2012 Jul 23. Clin Cancer Res. 2012. PMID: 22825582 Free PMC article.

3

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

Hyman DM, Eaton AA, Gounder MM, Smith GL, Pamer EG, Hensley ML, Spriggs DR, Ivy P, Iasonos A. Hyman DM, et al. J Clin Oncol. 2014 Feb 20;32(6):519-26. doi: 10.1200/JCO.2013.49.8808. Epub 2014 Jan 13. J Clin Oncol. 2014. PMID: 24419130 Free PMC article.

4

Reply to M. Voskoboynik et al.

Hyman DM, Eaton AA, Gounder MM, Ivy SP, Iasonos A, Spriggs DR. Hyman DM, et al. J Clin Oncol. 2014 Oct 1;32(28):3199-200. doi: 10.1200/JCO.2014.56.5762. Epub 2014 Jul 28. J Clin Oncol. 2014. PMID: 25071117 No abstract available.

5

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.

Hyman DM, Eaton AA, Gounder MM, Pamer EG, Pettiford J, Carvajal RD, Ivy SP, Iasonos A, Spriggs DR. Hyman DM, et al. Oncotarget. 2015 Aug 7;6(22):19316-27. doi: 10.18632/oncotarget.2909. Oncotarget. 2015. PMID: 25682870 Free PMC article. Clinical Trial.

6

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.

Eaton A, Iasonos A, Gounder MM, Pamer EG, Drilon A, Vulih D, Smith GL, Ivy SP, Spriggs DR, Hyman DM. Eaton A, et al. Among authors: hyman dm. Clin Cancer Res. 2016 Feb 1;22(3):553-9. doi: 10.1158/1078-0432.CCR-15-0339. Epub 2015 Aug 31. Clin Cancer Res. 2016. PMID: 26324741 Free PMC article.

7

Reply to M.P. Decatris et al.

Hyman DM, Solit DB, Iasonos A. Hyman DM, et al. J Clin Oncol. 2016 Mar 10;34(8):887. doi: 10.1200/JCO.2015.65.2487. Epub 2016 Jan 11. J Clin Oncol. 2016. PMID: 26755514 No abstract available.

8

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.

Drilon A, Eaton AA, Schindler K, Gounder MM, Spriggs DR, Harris P, Ivy SP, Iasonos A, Lacouture ME, Hyman DM. Drilon A, et al. Among authors: hyman dm. Cancer. 2016 Apr 15;122(8):1228-37. doi: 10.1002/cncr.29918. Epub 2016 Feb 24. Cancer. 2016. PMID: 26916138 Free PMC article.

9

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.

Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND. Hyman DM, et al. Cancer. 2012 Aug 1;118(15):3703-9. doi: 10.1002/cncr.26655. Epub 2011 Dec 2. Cancer. 2012. PMID: 22139894 Free PMC article.

10

BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.

Grisham RN, Iyer G, Garg K, Delair D, Hyman DM, Zhou Q, Iasonos A, Berger MF, Dao F, Spriggs DR, Levine DA, Aghajanian C, Solit DB. Grisham RN, et al. Among authors: hyman dm. Cancer. 2013 Feb 1;119(3):548-554. doi: 10.1002/cncr.27782. Epub 2012 Aug 28. Cancer. 2013. PMID: 22930283 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

204 results

Search Page

Filters